Dupilumab: initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks
Study summary
Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.
Eligibility
Sex
ALL
Min age
4 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria:
Enrolled patients were required to have been on regular ICS-LABA therapy for at least 3-6 months without adequate control. The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl. All children were prescribed with dupilumab during the study period.
Exclusion Criteria:
Patients with conditions other than asthma receiving treatment with dupilumab, individuals currently using other biologics or undergoing sublingual or subcutaneous immunotherapy, active parasitic infections, and children with immunodeficiency were excluded.
Primary outcome measure(s)
FEV1 — From enrollment to the end of treatment through study completion, an average of 1 year forced expiratory volume in one second
FVC — From enrollment to the end of treatment through study completion, an average of 1 year forced vital capacity
FEV1/FVC — From enrollment to the end of treatment through study completion, an average of 1 year ratio of forced expiratory volume in onesecond to forced vital capacity
PEF — From enrollment to the end of treatment through study completion, an average of 1 year peak expiratory flow
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.